Resiquimod clinical trials
Also written R848.
How each study uses resiquimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the resiquimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
16 studies that test it; most in 2004 (4)
| Year | Studies |
|---|---|
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 1 |
| 2009 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2017 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 7
Graceway Pharmaceuticals, LLC (6) · Mayo Clinic (2) · University of British Columbia (2) · Cambridge University Hospitals NHS Foundation Trust (1) · Galderma R&D (1) · Abramson Cancer Center at Penn Medicine (1) · Celldex Therapeutics (1) · Spirig Pharma Ltd. (1)
Often tested with
Tested in the same studies.
Resiquimod Gel CD11301 (1) · Gag:267-274 Peptide Vaccine (1) · Rasdegafusp alfa (1) · Poly ICLC (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test resiquimod.
- Apr 2027Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)Not applicable · Akhilesh Jha
Studies
Open first, then newest update. How each study uses resiquimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)RecruitingNot applicableAkhilesh JhaNCT06488118Written as R848How we know
- Nasal Immune Challenge StudyActive, not recruitingNot applicableCambridge University Hospitals NHS Foundation TrustNCT06021002Written as R848How we know
- A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)CompletedPhase 2Galderma R&DNCT03292406Written as CD11301 0.03%How we know
- Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)CompletedPhase 1/2Abramson Cancer Center at Penn MedicineNCT01676831Written as Topical resiquimod 0.06%How we know
- Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By SurgeryCompletedEarly Phase 1Mayo ClinicNCT01748747Written as resiquimodHow we know
- A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1CompletedPhase 1/2Celldex TherapeuticsNCT00948961Written as CDX-1401 in combination with Resiquimod and/or Poly-ICLCHow we know
- Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis LesionsCompletedPhase 2Spirig Pharma Ltd.NCT01583816Written as Resiquimod 0.03%How we know
- Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by SurgeryCompletedEarly Phase 1Mayo ClinicNCT00470379Written as resiquimodHow we know
- Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) AgonistsCompletedPhase 1University of British ColumbiaNCT01737580Written as resiquimodHow we know
- Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune ModulatorCompletedPhase 1/2University of British ColumbiaNCT00175435Written as Resiquimod gelHow we know
- An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric SubjectsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00116662Written as ResiquimodHow we know
- Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in AdultsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00114920Written as ResiquimodHow we know
- Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in AdultsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00115141Written as ResiquimodHow we know
- Study With a Topical Gel to Treat Common Warts in AdultsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00117923Written as ResiquimodHow we know
- Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric SubjectsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00116675Written as ResiquimodHow we know
- Study With a Topical Gel to Treat Common Warts in AdultsCompletedPhase 2Graceway Pharmaceuticals, LLCNCT00117871Written as ResiquimodHow we know
Codes
What other systems call resiquimod · ClinicalTrials.gg INT004198
- MeSH (NLM) C402365resiquimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) V3DMU7PVXFRESIQUIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q426054resiquimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C63958ResiquimodOne source FDA
- DrugBank DB06530One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C402365 | resiquimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | V3DMU7PVXF | RESIQUIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q426054 | resiquimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C63958 | Resiquimod | One source FDA |
| DrugBank | DB06530 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.